The DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index; 161 of the 331 sources its claims cite were checked for support.
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Open accessAbstract
OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1 RA), dual Glucose-dependent Insulinotropic Polypeptide/Glucagon-like Peptide-1 (GIP/GLP-1) agonists, and emerging triple agonists, has facilitated a shift from weight-centric goals to precision-based obesity care. This review provides a clinical framework for pharmacologic treatment, organized by phenotype, obesity-related complications, age, and behavioral traits. DESIGN: Narrative review of randomized trials, meta-analyses, real-world evidence, and international guidelines through May 2025. Evidence was synthesized across key obesity phenotypes, cardiometabolic, hepatic, renal, mechanical, behavioral, and stratified by life stage, including pediatric, reproductive-age, and older adults, with attention to safety, cost-effectiveness, and special populations. RESULTS: In established Atherosclerotic Cardiovascular Disease, semaglutide significantly reduces major adverse cardiovascular events. Tirzepatide offers cardiometabolic benefits for high-risk people without overt disease. Both agents improve symptoms and function in Heart Failure with Preserved Ejection Fraction, irrespective of glycemia or weight loss. In Chronic Kidney Disease, they decrease albuminuria and eGFR decline. In Metabolic Dysfunction-Associated Steatotic Liver Disease, GLP-1 RAs and GIP/GLP-1 RAs demonstrate marked histological improvements. Mechanical complications such as osteoarthritis and sleep apnea are improved by anti-obesity medications-induced weight loss. GLP-1 RAs and naltrexone/bupropion prove effective against binge and emotional eating. In youths, liraglutide and semaglutide are both approved and effective. Liraglutide and orlistat preserve lean mass alongside resistance training and adequate protein intake in older and sarcopenic people. CONCLUSIONS: An anti-obesity treatment framework focused on both phenotype and complication burden improves the personalization of obesity care and supports clinical decision-making throughout a person’s lifespan.
Overview
CoChat Summary
TL;DR
This is a narrative review that proposes a phenotype- and complication-guided framework for choosing anti-obesity medications and bariatric surgery across the lifespan. It argues that obesity pharmacotherapy should be matched to comorbidities, behavior, age, and cost rather than BMI alone.
Key findings
- The review synthesizes 200 studies after screening 1,296 titles/abstracts and reviewing 212 full texts; no quantitative meta-analysis was performed.
- In established ASCVD, semaglutide 2.4 mg once weekly reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90) and all-cause mortality by 19% in people with obesity and established ASCVD without diabetes; in HFpEF, semaglutide improved KCCQ-CSS by +7.8 points and 6MWD by +20.3 m.
- In prediabetes, tirzepatide 15 mg once weekly produced 22.5% mean weight loss and a 94% risk reduction in diabetes progression over 72 weeks; in a separate trial, diabetes incidence was 1.3% vs 13.3% with placebo (HR 0.07).
- In MASH, semaglutide and tirzepatide showed major histologic benefits: semaglutide achieved 59% vs 17% MASH resolution in a phase 2 trial and 62.9% vs 34.3% steatohepatitis resolution without worsening fibrosis in ESSENCE; tirzepatide achieved 44%/56%/62% MASH resolution at 5/10/15 mg vs 10% placebo.
Methods
- Narrative review led by a multidisciplinary panel of endocrinologists, pediatricians, registered dietitians, and obesity medicine specialists.
- Literature searched from January 1998 to May 2025 across PubMed/MEDLINE, Scopus, Cochrane CENTRAL, ClinicalTrials.gov, regulatory sources (EMA/FDA), and manual journal searches; included RCTs, meta-analyses, observational studies, guidelines, and expert consensus documents in English.
- Evidence was organized by phenotype, complication, age/life stage, safety, and cost-effectiveness; recommendations were qualitatively labeled “should be preferred,” “may be considered,” or “not recommended,” with no quantitative meta-analysis.
Limitations
- The paper states that direct head-to-head trials between anti-obesity medications are lacking, limiting comparative conclusions.
- It states that behavioral and psychosocial phenotypes are underrepresented in major trials, which constrains generalizability.
- It states that cost-effectiveness models are highly context-specific and may not extrapolate across healthcare systems.
- Evident from the text: this is a narrative review rather than a de novo clinical trial, so conclusions depend on the quality and heterogeneity of the underlying studies (this is evident from the design and synthesis approach).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
140 Valid · 24 Not valid · 150 Not checked · 63 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Approved by FDA/EMA from age 12.”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Stratification in vulnerable ages > 12–18 years
What the sources say
- Disputedcites [113] Weghuber D, Barrett T, Barrientos-Pérez M et al (2022) Once-weekly semaglutide in adolescents with obesity. N Engl J Med 387:2245–2257 sourceExperimental — accuracy not yet measured
The paper’s introductory passage in the Abstract > Conclusions section says that, for adolescents aged 12 or older, the FDA had approved liraglutide, orlistat, and phentermine–topiramate, while the EMA had approved only liraglutide. It describes semaglutide 2.4 mg as approved for adults, not adolescents. No page numbers are available in our copy. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Micronutrient optimization, especially with ≥ 800 IU/day of vitamin D and adequate calcium, is important for muscle function and fall prevention [119].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Stratification in vulnerable ages > Sarcopenic obesity
What the sources say
- Disputedcites [119] Bischoff-Ferrari HA, Vellas B, Rizzoli R et al (2020) Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA 324:1855–1868 sourceExperimental — accuracy not yet measured
The Conclusions report that 2000 IU/day of vitamin D did not significantly improve physical performance in adults aged 70 or older without major comorbidities, contrary to the claimed muscle-function benefit in this trial population. The paper does not establish that vitamin D plus adequate calcium prevents falls: calcium was not a randomized intervention, and falls were not among the reported primary outcomes (Study Participants; Primary End Points). (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“No benefits on hirsutism are to be expected [161].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Special populations > Polycystic ovary syndrome (PCOS)
What the sources say
- Disputedcites [161] Teede HJ, Tay CT, Laven JJE et al (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 108:2447–2469 sourceExperimental — accuracy not yet measured
The guideline's recommendation 4.7.2 (Materials and Methods; page not available) says metformin should be considered over inositol for hirsutism, contrary to the categorical claim that no benefit is expected. Recommendations 4.4.1 and 4.4.5 favor oral contraceptives for hirsutism and note that other interventions may be needed, but do not say metformin has no benefit. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In STEP-HFpEF, semaglutide 2.4 OW improved Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) (+ 7.8 points), 6-minute walk distance (6MWD) (+ 20.3 m), reduced C Reactive Protein (CRP) (−43.5% vs. −7.3%) and body weight (− 13.3% vs. − 2.6%), and showed a lower, though exploratory, HF event rate (HR 0.08; 95% CI 0.00–0.42) [5].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Cardio renal metabolic complication-based pharmacotherapy > Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl
What the sources say
- Supportedcites [5] Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069–1084 source
The Results and Confirmatory Secondary End Points report the cited 7.8-point KCCQ-CSS difference, 20.3-m 6-minute walk difference, CRP reductions of 43.5% versus 7.3%, and weight changes of −13.3% versus −2.6%. Supportive Secondary and Exploratory End Points report fewer adjudicated heart-failure events with semaglutide (HR 0.08; 95% CI, 0.00–0.42). The Conclusions specify that these findings concern patients with HFpEF and obesity. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The LIGHT trial was terminated early; the impact of MACE remains unknown [15].”
§ Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan > Cardio renal metabolic complication-based pharmacotherapy > Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl
What the sources say
- Supportedcites [15] Nissen SE, Wolski KE, Prcela L et al (2016) Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315:990–1004 source
The Discussion states that the LIGHT trial ended prematurely and that its findings could not establish the prespecified noninferiority criterion. The Conclusions state that, because of the early termination, the cardiovascular safety of naltrexone-bupropion remains uncertain. Page numbers were not provided in our copy. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
168 more claims · 72 with their cited sources checked
Create a free account to see all 377 claims and to verify the 27 references still open.
- It may state two separate claims as one. 175
- The quote only partly states this claim. 2
- Probably not a substantial claim. 43
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Naude J, Zentner A, Suresh P et al (2024) Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study. Int J Obes (Lond) 48:1118–1125”
Cited work 10.1038/s41366-024-01526-2 · retracted 2025-12-19 · notice 10.1038/s41366-025-02006-x · this paper published 2025-11-10
Citations
Cites
1 retracted
Naude, J., Zentner, A., Suresh, P., Bittman, J., & Khan, N. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01526-2 · Cited by 13
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“The Diabetes Prevention Program showed that metformin 850 mg BID reduced T2D incidence by 31% over 2.8 years, with greater benefits for younger people with higher Body Mass Index (BMI) [24 ].”
InfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Based on the MACE reduction observed in SUSTAIN 6 [30], it should be preferred in patients with established ASCVD (secondary prevention).”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 5×
“Across major trials, women, especially pre - menopausal, tend to experience greater relative weight loss with GLP-1 RAs and dual incretin therapies such as tirz-epatide [2, 3 ].”
InfluentialThe prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Research works printed but not linked: 2
- Castano GSS (2024) Real-world implications and limitations of GLP-1 prescriptions in adolescents. J Endocr Soc 8(Suppl 1):bae163.1506. https://doi.org/10.1210/jendso/bae163.1506. (PMCID: PMC11454784) · doi:10.1210/jendso/bae163.1506
- Website ICER, Accessed June 17, 2025. [Online]. Available: https://icer.org/news-insights/journal-articles/cost-effectiveness-of-oral-semaglutide-added-to-current-antihyperglycemic-treatment-for-type-2-diabetes
Cited by
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
“172 Beyond their effects on appetite, weight loss, and glycemic control, emerging evidence indicates that GLP-1RAs may modulate the gut microbiota.”
Self-citationAsia at the Epicenter of the Global Cardiometabolic Shift
Khanna, S., Gan, G. C. H., Sindone, A. P., Tromp, J., Butler, J., Foo, R., Nerlekar, N., & Bhat, A. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.001 · Cited by 19
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“Patients with prominent metabolic comorbidities such as MASLD may derive additional benefit from dual GLP-1/glucagon or triple agonist approaches [119 – 121].”
InfluentialWu, X., Yuan, C., Wang, H., Pan, X., Wang, R., Cai, Q., Huang, Y., Ren, J., Kang, J., Cheng, M., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121247 · Cited by 2
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Metadata
- Authors
- Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U.
- Affiliations
- Università Campus Bio-Medico (IT)
- Sapienza University of Rome (IT)
- University of Bologna (IT)
- Campus Bio Medico University Hospital (IT)
- Bambino Gesù Children's Hospital (IT)
- Corresponding author
- Tuccinardi, Dario
- Watanabe, Mikiko
- Venue
- Journal of Endocrinological Investigation
- Published
- 2025-11-10
- Volume
- 48
- Issue
- 12
- Pages
- 2761-2798
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC12640352
- OpenAlex
- W4416063077
- Semantic Scholar
- bf46b2f618e8d68babaa99cd8a63d006d43a6b66
- Cited by
- 29
- References
- 194
- Citations by year
- 2026: 28 · 2025: 1
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- Funders
- EUROPEAN UNION (NextGenerationEU, under the Italian Ministry of University and Research (MUR) PRIN 2022 program, Mission 4, Component 1, CUP C53D23006490001.)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, precision medicine, obesity phenotypes, obesity pharmacotherapy, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, semaglutide, tirzepatide, liraglutide, orlistat, naltrexone/bupropion, cardiometabolic complications, heart failure with preserved ejection fraction, chronic kidney disease, non-alcoholic fatty liver disease, sleep apnea, osteoarthritis, binge eating, emotional eating, childhood obesity, sarcopenia, older adults, weight loss
- MeSH terms
- Tirzepatide, Semaglutide, Humans, Longevity, Obesity, Phenotype, Anti-Obesity Agents, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. https://app.cochat.ai/papers/10.1007/s40618-025-02700-7
- The paper
- Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025). Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-025-02700-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.